Neurogene Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGNE research report →
Companywww.neurogene.com
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease.
- CEO
- Rachel L. McMinn
- IPO
- 2014
- Employees
- 107
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $432.02M
- P/E
- -6.18
- P/S
- 0.00
- P/B
- 2.56
- EV/EBITDA
- -3.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.88%
- ROIC
- -44.78%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-90,351,000 · -20.24%
- EPS
- $-4.24 · 0.93%
- Op Income
- $-103,208,000
- FCF YoY
- -9.73%
Performance & Tape
- 52W High
- $37.27
- 52W Low
- $14.65
- 50D MA
- $24.61
- 200D MA
- $22.31
- Beta
- 2.08
- Avg Volume
- 184.18K
Get TickerSpark's AI analysis on NGNE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 26 | Cvijic Christine Mikail | sell | 4,800 |
| May 6, 26 | Cvijic Christine Mikail | sell | 4,800 |
| May 5, 26 | Shafer Christina | other | 120,000 |
| Apr 20, 26 | Shafer Christina | other | 0 |
| Mar 26, 26 | Cvijic Christine Mikail | sell | 2,558 |
| Mar 26, 26 | McMinn Rachel | sell | 3,352 |
| Mar 26, 26 | Jordan Julie | sell | 828 |
| Mar 13, 26 | Cobb Stuart | sell | 3,991 |
| Mar 13, 26 | Cobb Stuart | sell | 2,658 |
| Mar 13, 26 | Cobb Stuart | sell | 148 |
Our NGNE Coverage
We haven't published any research on NGNE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NGNE Report →